文献速递产科母胎医学

妊娠期SARS-CoV-2感染与子痫前期风险:系统综述与Meta分析

SARS-CoV-2 infection during pregnancy and risk of preeclampsia: a systematic review and meta-analysis.
PubMed 文献 · Am J Obstet Gynecol · 2021-07-21

该系统综述与Meta分析纳入28项观察性研究、共790,954例孕妇,其中15,524例确诊SARS-CoV-2感染。分析显示妊娠期SARS-CoV-2感染与子痫前期风险显著升高相关(合并未调整OR 1.62,95%CI 1.45-1.82),调整后OR 1.58(95%CI 1.39-1.80),且与重度特征子痫前期、子痫及HELLP综合征风险升高相关。

要点

  • 妊娠期SARS-CoV-2感染与子痫前期风险显著升高相关(合并未调整OR 1.62)。
  • 调整混杂因素后关联仍显著(合并调整OR 1.58,95%CI 1.39-1.80)。
  • 有症状感染者的子痫前期风险(OR 2.11)高于无症状感染者(OR 1.59)。

核心结论

  • 妊娠期SARS-CoV-2感染与子痫前期风险升高显著相关,且与重度特征子痫前期、子痫及HELLP综合征风险升高相关。

主要发现

  • 未调整OR分析显示,感染组子痫前期发生率为7.0%,未感染组为4.8%,合并OR 1.62(95%CI 1.45-1.82;P<.00001;I²=17%;26项研究;95%预测区间1.28-2.05)。
  • 调整OR分析显示,妊娠期SARS-CoV-2感染与子痫前期风险升高相关(合并OR 1.58;95%CI 1.39-1.80;P<.0001;I²=0%;11项研究)。
  • 重度特征子痫前期风险升高(OR 1.76;95%CI 1.18-2.63;I²=58%;7项研究),子痫风险升高(OR 1.97;95%CI 1.01-3.84;I²=0%;3项研究),HELLP综合征风险升高(OR 2.10;95%CI 1.48-2.97;1项研究)。
  • 有症状感染者子痫前期风险(OR 2.11;95%CI 1.59-2.81)高于无症状感染者(OR 1.59;95%CI 1.21-2.10)。

关键数值与推荐

  • 纳入标准:评估妊娠期SARS-CoV-2感染与子痫前期关联的观察性研究,报告未调整和/或调整风险估计值及95%CI或可计算数据。
  • 主要结局为子痫前期;次要结局包括重度特征子痫前期、非重度特征子痫前期、子痫及HELLP综合征。
  • 异质性用I²统计量量化,I²≥30%表示存在实质性异质性。

临床怎么用

  • 对妊娠期SARS-CoV-2感染者应加强子痫前期监测与评估,尤其是有症状感染者。

局限性

  • 纳入研究多为观察性设计,可能存在残余混杂。
  • 部分结局(如HELLP综合征、子痫)纳入研究数量少,估计值不确定性较大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the relationship between SARS-CoV-2 infection during pregnancy and the risk for preeclampsia. DATA SOURCES: MEDLINE, Embase, POPLINE, CINAHL, LILACS, and the World Health Organization COVID-19, Chinese, and preprint databases (all from December 1, 2019, to May 31, 2021). Google Scholar, bibliographies, and conference proceedings were also searched. STUDY ELIGIBILITY CRITERIA: Observational studies that assessed the association between SARS-CoV-2 infection during pregnancy and preeclampsia and that reported unadjusted and/or adjusted risk estimates and 95% confidence intervals or data to calculate them. STUDY APPRAISAL AND SYNTHESIS METHODS: The primary outcome was preeclampsia. Secondary outcomes included preeclampsia with severe features, preeclampsia without severe features, eclampsia, and hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome. Two reviewers independently reviewed studies for inclusion, assessed their risk of bias, and extracted data. Pooled unadjusted and adjusted odds ratios with 95% confidence intervals, and 95% prediction interval were calculated. Heterogeneity was quantified using the І2 statistic, for which І2≥30% indicated substantial heterogeneity. Subgroup and sensitivity analyses were performed to test the robustness of the overall findings. RESULTS: A total of 28 studies comprising 790,954 pregnant women, among which 15,524 were diagnosed with SARS-CoV-2 infection, met the inclusion criteria. The meta-analysis of unadjusted odds ratios showed that the odds of developing preeclampsia were significantly higher among pregnant women with SARS-CoV-2 infection than among those without SARS-CoV-2 infection (7.0% vs 4.8%; pooled odds ratio, 1.62; 95% confidence interval, 1.45-1.82; P<.00001; І2=17%; 26 studies; 95% prediction interval of the odds ratio, 1.28-2.05). The meta-analysis of adjusted odds ratios also showed that SARS-CoV-2 infection during pregnancy was associated with a significant increase in the odds of preeclampsia (pooled odds ratio, 1.58; 95% confidence interval, 1.39-1.80; P<.0001; І2=0%; 11 studies). There was a statistically significant increase in the odds of preeclampsia with severe features (odds ratio, 1.76; 95% confidence interval, 1.18-2.63; І2=58%; 7 studies), eclampsia (odds ratio, 1.97; 95% confidence interval, 1.01-3.84; І2=0%, 3 studies), and HELLP syndrome (odds ratio, 2.10; 95% confidence interval, 1.48-2.97; 1 study) among pregnant women with SARS-CoV-2 infection when compared to those without the infection. Overall, the direction and magnitude of the effect of SARS-CoV-2 infection during pregnancy on preeclampsia was consistent across most prespecified subgroup and sensitivity analyses. Both asymptomatic and symptomatic SARS-CoV-2 infections significantly increased the odds of developing preeclampsial; however, it was higher among patients with symptomatic illness (odds ratio, 2.11; 95% confidence interval, 1.59-2.81) than among those with asymptomatic illness (odds ratio, 1.59; 95% confidence interval, 1.21-2.10). CONCLUSION: SARS-CoV-2 during pregnancy is associated with higher odds of preeclampsia.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Conde-Agudelo A, Romero R. SARS-CoV-2 infection during pregnancy and risk of preeclampsia: a systematic review and meta-analysis. Am J Obstet Gynecol. 2021. PMID: 34302772. doi:10.1016/j.ajog.2021.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。